nach oben

NeuroMolecular Medicine

Erschienen in:

01.09.2008 | Original Paper

Perturbed Autonomic Nervous System Function in Metabolic Syndrome

verfasst von: Nicholas Tentolouris, Georgia Argyrakopoulou, Nicholas Katsilambros

Erschienen in: NeuroMolecular Medicine | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The metabolic syndrome is characterized by the clustering of various common metabolic abnormalities in an individual and it is associated with increased risk for the development of type 2 diabetes and cardiovascular diseases. Its prevalence in the general population is approximately 25%. Central fat accumulation and insulin resistance are considered as the common denominators of the abnormalities of the metabolic syndrome. Subjects with metabolic syndrome have autonomic nervous system dysfunction characterized by predominance of the sympathetic nervous system in many organs, i.e. heart, kidneys, vasculature, adipose tissue, and muscles. Sympathetic nervous system activation in metabolic syndrome is detected as increased heart rate and blood pressure, diminished heart rate variability, baroreceptor dysfunction, enhanced lipolysis in visceral fat, increased muscle sympathetic nerve activity, and high urine or plasma catecholamine concentrations as well as turnover rates. The augmented sympathetic activity in individuals with metabolic syndrome worsens prognosis of this high-risk population. The mechanisms linking metabolic syndrome with sympathetic activation are complex and not clearly understood. Whether sympathetic overactivity is involved in the development of the metabolic syndrome or is a consequence of it remains to be elucidated since data from prospective studies are missing. Intervention studies have demonstrated that the autonomic disturbances of the metabolic syndrome may be reversible.

Aldo Ferrara, L., Guida, L., Ferrara, F., et al. (2007). Blood pressure at rest, during 24 h monitoring and in response to sympathetic stimulation in hypertensive patients with metabolic syndrome. International Journal of Cardiology, 117, 312–316.PubMedCrossRef

Alvarez, G. E., Beske, S. D., Ballard, T. P., & Davy, K. P. (2002). Sympathetic neural activation in visceral obesity. Circulation, 106, 2533–2536.PubMedCrossRef

Anderson, E. A., Hoffman, R. P., Balon, T. W., Sinkey, C. A., & Mark, A. L. (1991). Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. Journal of Clinical Investigation 87, 2246–2252.PubMedCrossRef

Aso, Y., Wakabayashi, S., Nakano, T., Yamamoto, R., Takebayashi, K., & Inukai, T. (2006). High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism 55, 1014–1021.PubMedCrossRef

Assmann, G., Guerra, R., Fox, G., et al. (2007). Harmonizing the definition of the metabolic syndrome: Comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. American Journal of Cardiology 99, 541–548.PubMedCrossRef

Bernardi, L., Ricordi, L., Lazzari, P., et al. (1992). Impaired circardian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation, 86, 1443–1452.PubMed

Berne, C., Fagius, J., & Niklasson, F. (1989). Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. Journal of Clinical Investigation, 84, 1403–1409.PubMedCrossRef

Berne, C., Fagius, J., Pollare, T., & Hjemdahl, P. (1992). The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia, 35, 873–879.PubMedCrossRef

Beske, S. D., Alvarez, G. E., Ballard, T. P., & Davy, K. P. (2002). Reduced cardiovagal baroreflex gain in visceral obesity: Implications for the metabolic syndrome. American Journal of Physiology-Heart and Circulatory Physiology, 282, H630–635.PubMed

Bianchi, C., Penno, G., Malloggi, L., et al. (2008). Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. Nutrition Metabolism and Cardiovascular Diseases, 18, 31–38.CrossRef

Boguszewski, M. C., Johannsson, G., Fortes, L. C., & Sverrisdottir, Y. B. (2004). Low birth size and final height predict high sympathetic nerve activity in adulthood. Journal of Hypertension 22, 1157–1163.PubMedCrossRef

Boulton, A. J., Vinik, A. I., Arezzo, J. C., et al. (2005). American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 28, 956–962.PubMedCrossRef

Branth, S., Ronquist, G., Stridsberg, M., et al. (2007). Development of abdominal fat and incipient metabolic syndrome in young healthy men exposed to long-term stress. Nutrition Metabolism and Cardiovascular Diseases, 17, 427–435.CrossRef

Brunner, E. J., Hemingway, H., Walker, B. R., et al. (2002). Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: Nested case-control study. Circulation 106, 2659–2665.PubMedCrossRef

Busetto, L., Digito, M., Dalla Monta, P., Carraro, R., & Enzi, G. (1993). Omental and epigastric adipose tissue lipolytic activity in human obesity. Effect of abdominal fat distribution and relationship with hyperinsulinemia. Hormone and Metabolic Research, 25, 365–371.PubMed

Chaiken, R. L., & Banerji, M. A. (2006). Metabolic syndrome. In C. S. Mantzoros (Ed.), Obesity and diabetes (pp. 155–168). Totowa, NJ: Humana.

Chan, J. L., Mietus, J. E., Raciti, P. M., Goldberger, A. L., & Mantzoros, C. S. (2007). Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clinical Endocrinology (Oxford), 66, 49–57.

Chew, G. T., Gan, S. K., & Watts, G. F. (2006). Revisiting the metabolic syndrome. Medical Journal of Australia 185, 445–449.PubMed

Correia, M. L., & Rahmouni, K. (2006). Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obesity & Metabolism, 8, 603–610.CrossRef

Dalla Pozza, R. D., Bechtold, S., Putzker, S., Bonfig, W., Netz, H., & Schwarz, H. P. (2006). Young adults born small for gestational age: Is reduced baroreceptor sensitivity a risk factor for hypertension? Clinical Cardiology, 29, 215–218.PubMedCrossRef

Day, C. (2007). Metabolic syndrome, or What you will: Definitions and epidemiology. Diabetics & Vascular Disease Research, 4, 32–38.CrossRef

DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique: A method for quantifying insulin secretion and resistance. American Journal of Physiology, 237, E214–223.PubMed

Ducimetiere, P., Eschwege, E., Papoz, L., Richard, J. L., Claude, J. R., & Rosselin, G. (1980). Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia, 19, 205–210.PubMedCrossRef

Emdin, M., Gastaldelli, A., Muscelli, E., et al. (2001). Hyperinsulinemia and autonomic nervous system dysfunction in obesity: Effects of weight loss. Circulation, 103, 513–519.PubMed

Esler, M., Ferrier, C., Lambert, G., Eisenhofer, G., Cox, H., & Jennings, G. (1991). Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension, 17(Suppl), III29–III35.PubMed

Fehm, H. L., Kern, W., & Peters, A. (2006). The selfish brain: Competition for energy resources. Progress in Brain Research, 153, 129–140.PubMedCrossRef

Ferraro, S., Fazio, S., Santomauro, M., et al. (1990). Cardiac function and sympathetic activity in young diabetics. Diabetes Research and Clinical Practice, 8, 91–99.PubMedCrossRef

Frontoni, S., Bracaglia, D., & Gigli, F. (2005). Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutrition Metabolism and Cardiovascular Diseases, 15, 441–449.CrossRef

Fulop, T., Tessier, D., & Carpentier, A. (2006). The metabolic syndrome. Pathologie Biologie (Paris) 54, 375–386.CrossRef

Gadegbeku, C. A., Dhandayuthapani, A., Sadler, Z. E., & Egan, B. M. (2002). Raising lipids acutely reduces baroreflex sensitivity. American Journal of Hypertension, 15, 479–485.PubMedCrossRef

Galletti, F., Barbato, A., Versiero, M., et al. (2007). Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: An 8-year follow-up study. Journal of Hypertension, 25, 1671–1677.PubMedCrossRef

Grassi, G. (1998). Role of the sympathetic nervous system in human hypertension. Journal of Hypertension, 16, 1979–1987.PubMedCrossRef

Grassi, G. (2006). Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertension Research, 29, 839–847.PubMedCrossRef

Grassi, G., Dell’Oro, R., Facchini, A., Quarti Trevano, F., Bolla, G. B., & Mancia, G. (2004). Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. Journal of Hypertension, 22, 2363–2369.PubMedCrossRef

Grassi, G., Dell’Oro, R., Quarti-Trevano, F., et al. (2005). Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia, 48, 1359–1365.PubMedCrossRef

Grassi, G., Quarti-Trevano, F., Seravalle, G., & Dell’oro, R. (2007). Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutrition Metabolism and Cardiovascular Diseases, 17, 473–481.CrossRef

Grassi, G., & Seravalle, G. (2006). Autonomic imbalance and metabolic syndrome: Unravelling interactions, mechanisms and outcomes. Journal of Hypertension, 24, 47–49.PubMedCrossRef

Grassi, G., Seravalle, G., Bertinieri, G., et al. (2000). Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. Journal of Hypertension, 18, 587–593.PubMedCrossRef

Hayes, L., Pearce, M. S., & Unwin, N. C. (2006). Lifecourse predictors of normal metabolic parameters in overweight and obese adults. International Journal of Obesity (London), 30, 970–976.CrossRef

Haynes, W. G. (2000). Interaction between leptin and sympathetic nervous system in hypertension. Current Hypertension Reports, 2, 311–318.PubMedCrossRef

Hoffstedt, J., Wahrenberg, H., Thorne, A., & Lonnqvist, F. (1996). The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue. Diabetologia 39, 838–844.PubMedCrossRef

Holl, R. W., Pavlovic, M., Heinze, E., & Thon, A. (1999). Circadian blood pressure during the early course of type 1 diabetes. Analysis of 1,011 ambulatory blood pressure recordings in 354 adolescents and young adults. Diabetes Care, 22, 1151–1157.PubMedCrossRef

Howard, G., O’Leary, D. H., Zaccaro, D., et al. (1996). Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation, 93, 1809–1817.PubMed

Huggett, R. J., Burns, J., Mackintosh, A. F., & Mary, D. A. (2004). Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension, 44, 847–852.PubMedCrossRef

Ikeda, T., Matsubara, T., Sato, Y., & Sakamoto, N. (1993). Circadian blood pressure variation in diabetic patients with autonomic neuropathy. Journal of Hypertension, 11, 581–587.PubMedCrossRef

Iribarren, C., Go, A. S., Husson, G., et al. (2006). Metabolic syndrome and early-onset coronary artery disease: Is the whole greater than its parts? Journal of the American College of Cardiology, 48, 1800–1807.PubMedCrossRef

Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005). The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 28, 2289–2304.PubMedCrossRef

Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. Journal of Clinical Investigation, 106, 473–481.PubMedCrossRef

Ko, G. T., Cockram, C. S., Chow, C. C., et al. (2006). Metabolic syndrome by the international diabetes federation definition in Hong Kong Chinese. Diabetes Research and Clinical Practice, 73, 58–64.PubMedCrossRef

Kreier, F., Yilmaz, A., Kalsbeek, A., et al. (2003). Hypothesis: Shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes, 52, 2652–2656.PubMedCrossRef

Lembo, G., Napoli, R., Capaldo, B., et al. (1992). Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. Journal of Clinical Investigation, 90, 24–29.PubMedCrossRef

Lembo, G., Rendina, V., Iaccarino, G., Lamenza, F., Volpe, M., & Trimarco, B. (1993). Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. Hypertension, 21, 1015–1019.PubMed

Liao, D., Sloan, R. P., Cascio, W. E., et al. (1998). Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care, 21, 2116–2122.PubMedCrossRef

Liatis, S., Tentolouris, N., & Katsilambros, N. (2004). Cardiac autonomic nervous system activity in obesity. Pediatric Endocrinology Review, 1(Suppl 3), 476–483.

Lindgren, K., Hagelin, E., Hansen, N., & Lind, L. (2006). Baroreceptor sensitivity is impaired in elderly subjects with metabolic syndrome and insulin resistance. Journal of Hypertension, 24, 143–150.PubMedCrossRef

Lopes, H. F., Silva, H. B., Consolim-Colombo, F. M., et al. (2000). Autonomic abnormalities demonstrable in young normotensive subjects who are children of hypertensive parents. Brazilian Journal of Medical and Biological Research, 33, 51–54.PubMedCrossRef

Lopes, H. F., Stojiljkovic, M. P., Zhang, D., Goodfriend, T. L., & Egan, B. M. (2001). The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. American Journal of Hypertension, 14, 1032–1037.PubMedCrossRef

Lu, B., Yang, Y., Song, X., et al. (2006). An evaluation of the International Diabetes Federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus. Metabolism, 55, 1088–1096.PubMedCrossRef

Maison, P., Byrne, C. D., Hales, C. N., Day, N. E., & Wareham, N. J. (2001). Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care, 24, 1758–1763.PubMedCrossRef

Mancia, G., Bousquet, P., Elghozi, J. L., et al. (2007a). The sympathetic nervous system and the metabolic syndrome. Journal of Hypertension, 25, 909–920.PubMed

Mancia, G., Bombelli, M., Corrao, G., et al. (2007b). Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: Daily life blood pressure, cardiac damage, and prognosis. Hypertension, 49, 40–47.PubMedCrossRef

McNeill, A. M., Rosamond, W. D., Girman, C. J., et al. (2005). The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care, 28, 385–390.PubMedCrossRef

Meigs, J. B., Wilson, P. W., Nathan, D. M., D’Agostino, R. B., Sr., Williams, K., & Haffner, S. M. (2003). Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes, 52, 2160–2167.PubMedCrossRef

Monami, M., Marchionni, N., & Masotti, G., Mannucci, E. (2007). IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obesity & Metabolism, 9, 350–353.CrossRef

Modan, M., & Halkin, H. (1991). Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care, 14, 470–487.PubMedCrossRef

Morgan, D. A., Balon, T. W., Ginsberg, B. H., & Mark, A. L. (1993). Nonuniform regional sympathetic nerve responses to hyperinsulinemia in rats. American Journal of Physiology, 264, R423–427.PubMed

Muntzel, M. S., Morgan, D. A., Mark, A. L., & Johnson, A. K. (1994). Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity. American Journal of Physiology, 267, R1350–R1355.PubMed

Nonogaki, K. (2000). New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia, 43, 533–549.PubMedCrossRef

O’Hare, J. A., Minaker, K. L., Meneilly, G. S., Rowe, J. W., Pallotta, J. A., & Young, J. B. (1989). Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men. Metabolism, 38, 322–329.PubMedCrossRef

Oda, E. (2006). The metabolic syndrome (emperor) wears no clothes: Response to Kahn. Diabetes Care, 29, 2566.PubMedCrossRef

Orchard, T. J., Eichner, J., Kuller, L. H., Becker, D. J., McCallum, L. M., & Grandits, G. A. (1994). Insulin as a predictor of coronary heart disease: Interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Annals of Epidemiology, 4, 40–45.PubMedCrossRef

Ostman, J., Arner, P., Engfeldt, P., & Kager, L. (1979). Regional differences in the control of lipolysis in human adipose tissue. Metabolism, 28, 1198–1205.PubMedCrossRef

Paolisso, G., Manzella, D., Rizzo, M. R., et al. (2000). Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. American Journal of Clinical Nutrition, 72, 723–730.PubMed

Perin, P. C., Maule, S., & Quadri, R. (2001). Sympathetic nervous system, diabetes, and hypertension. Clinical and Experimental Hypertension, 23, 45–55.PubMedCrossRef

Pikkujamsa, S. M., Huikuri, H. V., Airaksinen, K. E., et al. (1998). Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. American Journal of Hypertension, 11, 523–531.PubMedCrossRef

Pyorala, K. (1979). Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care, 2, 131–141.PubMedCrossRef

Qiao, Q. (2006). Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia, 49, 2837–2846.PubMedCrossRef

Rahmouni, K., & Morgan, D. A. (2007). Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension, 49, 647–652.PubMedCrossRef

Rathmann, W., Haastert, B., Icks, A., et al. (2006). Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: The KORA Survey 2000. Diabetes Care, 29, 461.PubMedCrossRef

Reaven, G. M. (1993). Role of insulin resistance in human disease (syndrome X): An expanded definition. Annual Review of Medicine, 44, 121–131.PubMedCrossRef

Reaven, G. M. (2006). The metabolic syndrome: Is this diagnosis necessary? American Journal of Clinical Nutrition, 83, 1237–1247.PubMed

Rowe, J. W., Young, J. B., Minaker, K. L., Stevens, A. L., Pallotta, J., & Landsberg, L. (1981). Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes, 30, 219–225.PubMed

Scherrer, U., Randin, D., Tappy, L., Vollenweider, P., Jequier, E., & Nicod, P. (1994). Body fat and sympathetic nerve activity in healthy subjects. Circulation, 89, 2634–2640.PubMed

Scherrer, U., & Sartori, C. (1997). Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation, 96, 4104–4113.PubMed

Scherrer, U., Vollenweider, P., Randin, D., Jequier, E., Nicod, P., & Tappy, L. (1993). Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation, 88, 388–394.PubMed

Skrapari, I., Tentolouris, N., Perrea, D., Bakoyiannis, C., Papazafiropoulou, A., & Katsilambros, N. (2007). Baroreflex sensitivity in obesity: Relationship with cardiac autonomic nervous system activity. Obesity (Silver Spring), 15, 1685–1693.CrossRef

Skyler, J. S., Marks, J. B., & Schneiderman, N. (1995). Hypertension in patients with diabetes mellitus. American Journal of Hypertension, 8(12 Pt 2), 100s–105s.PubMedCrossRef

Stein, P. K., Barzilay, J. I., Domitrovich, P. P., et al. (2007). The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: The Cardiovascular Health Study. Diabetic Medicine, 24, 855–863.PubMedCrossRef

Stern, M. P., Williams, K., Gonzalez-Villalpando, C., Hunt, K. J., & Haffner, S. M. (2004). Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care, 27, 2676–2681.PubMedCrossRef

Straznicky, N. E., Lambert, E. A., Lambert, G. W., Masuo, K., Esler, M. D., & Nestel, P. J. (2005). Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. The Journal of Clinical Endocrinology and Metabolism, 90, 5998–6005.PubMedCrossRef

Straznicky, N. E., Louis, W. J., McGrade, P., & Howes, L. G. (1993). The effects of dietary lipid modification on blood pressure, cardiovascular reactivity and sympathetic activity in man. Journal of Hypertension, 11, 427–437.PubMedCrossRef

Sundstrom, J., Vallhagen, E., Riserus, U., et al. (2006). Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care, 29, 1673–1674.PubMedCrossRef

Tentolouris, N., Liatis, S., & Katsilambros, N. (2006). Sympathetic system activity in obesity and metabolic syndrome. Annals of the New York Academy of Sciences, 1083, 129–152.PubMedCrossRef

Tentolouris, N., Tsigos, C., Perea, D., et al. (2003). Differential effects of high-fat and high-carbohydrate isoenergetic meals on cardiac autonomic nervous system activity in lean and obese women. Metabolism, 52, 1426–1432.PubMedCrossRef

Vollenweider, P., Randin, D., Tappy, L., Jequier, E., Nicod, P., & Scherrer, U. (1994). Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. Journal of Clinical Investigation, 93, 2365–2371.PubMedCrossRef

Vollenweider, P., Tappy, L., Randin, D., et al. (1993). Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. Journal of Clinical Investigation, 92, 147–154.PubMedCrossRef

Wannamethee, S. G., Shaper, A. G., Lennon, L., & Morris, R. W. (2005). Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine, 165, 2644–2650.PubMedCrossRef

Wingard, D. L., Barrett-Connor, E. L., & Ferrara, A. (1995). Is insulin really a heart disease risk factor. Diabetes Care, 18, 1299–1304.PubMed

Titel: Perturbed Autonomic Nervous System Function in Metabolic Syndrome
verfasst von: Nicholas Tentolouris
Georgia Argyrakopoulou
Nicholas Katsilambros
Publikationsdatum: 01.09.2008
Verlag: Humana Press Inc
Erschienen in: NeuroMolecular Medicine / Ausgabe 3/2008
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-008-8022-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Autonomic Control of the Aging Heart

The Molecular Basis of Familial Dysautonomia: Overview, New Discoveries and Implications for Directed Therapies

The Sympathetic Nervous System and Pain

Lack of Mitochondrial DNA Deletions in Lesions of Multiple Sclerosis

Neurotrophic Factors in Autonomic Nervous System Plasticity and Dysfunction